×
0 0 0 -0.00862068965517223 -0.0754310344827585 -0.0409482758620689 -0.0560344827586206 -0.063103448275862
Stockreport

Prima Biomed: Encouraging Data At SITC [Seeking Alpha]

PRIMA BIOMED (PBMD)  More Company Research Source: Seeking Alpha
PDF Prima Biomed: Encouraging Data At SITCSummaryShares are currently up 5% in the premarket session but have traded flat since my first article.New data for lead drug candidate IMP321 at SITC was encouraging.Tumor reductions were observed in 7 of 12 advanced metastatic melanoma patients (58%) who received IMP321 in combination with pembrolizumab.No treatment discontinuations due to adverse events or dose-limiting toxicities were observed. The high dose cohort (30 mg) is ongoing and I am looking forward to results here.Readers who are interested in the story and have done their due diligence should initiate a pilot position. Wait for technical strength to serve as confirmation to add. [Read more]

IMPACT SNAPSHOT EVENT TIME: PBMD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
PBMD alerts
from News Quantified
Opt-in for
PBMD alerts

from News Quantified
Opt-in for
PBMD alerts

from News Quantified